Can You Still Get Compounded Tirzepatide in 2026? Current FDA Status

Compounded tirzepatide is no longer a freely-available product in the United States. The FDA declared the tirzepatide shortage resolved on October 2, 2024^[1], and after the Outsourcing Facilities Association v FDA litigation (N.D. Tex. Case No. 4:24-cv-00953-O) ran to a preliminary-injunction denial on March 5, 2025^[3], FDA enforcement against mass-batch 503B compounding became active on March 19, 2025. 503A state-licensed pharmacies lost their enforcement-discretion window on February 18, 2025^[2]. Patient-specific 503A compounding remains legally available under a narrow exception — the prescriber must document a clinical need that the FDA-approved Zepbound or Mounjaro cannot meet for that specific patient — but “cheaper” is explicitly not a qualifying reason. This is what changed, what is still allowed, and what cash-pay patients on compounded tirzepatide should do next.

The honest summary

• Tirzepatide is off the FDA shortage list. The FDA's October 2, 2024 declaratory order found that Eli Lilly's stated supply could meet projected national demand^[1]. After the brief October–December 2024 re-evaluation triggered by the OFA lawsuit, FDA re-affirmed the shortage-resolved finding on December 19, 2024.
• 503B mass-batch compounding is now enforcement-prioritized. Outsourcing facilities had until March 19, 2025 to stop compounding tirzepatide from bulk drug substance. After that date the FDA can — and has — issued warning letters and enforcement actions against 503B facilities that continue^[2].
• 503A patient-specific compounding survives, narrowly. A state-licensed 503A pharmacy can still compound tirzepatide for an individually-identified patient if the prescriber documents that the FDA-approved product is not interchangeable for that patient — classic examples are a documented allergy to an excipient in commercial Zepbound or a strength not commercially available^[5]. Cost, supply convenience, and prescriber preference do not satisfy the standard.
• Cash-pay branded access has changed the economics. LillyDirect's Self Pay Journey Program launched February 23, 2026 at $299 (2.5 mg) / $399 (5 mg) / $449 (7.5–15 mg) per month for single-dose vials^[7], and Novo Nordisk's NovoCare Pharmacy ships Wegovy at $349 / month with a $199 introductory offer through June 30, 2026^[8]. The cash-pay gap between compounded and branded that drove the 2023–2024 market is much smaller in 2026.
• Compounded semaglutide is on a different track. Semaglutide was removed from the FDA shortage list in February 2025; 503A and 503B deadlines applied analogously. However, FDA's April 30, 2026 proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List on a finding of no clinical need^[4][9]signals that even a return to shortage would not re-open the door for outsourcing facilities.

Timeline: how we got here

• December 15, 2022. FDA added tirzepatide injection to the drug shortage list, opening the door for 503A and 503B compounding of the molecule.
• October 2, 2024. FDA published its declaratory order resolving the tirzepatide shortage^[1], with differentiated enforcement-discretion windows for 503A and 503B facilities.
• October 7, 2024. The Outsourcing Facilities Association and North American Custom Laboratories filed Outsourcing Facilities Association v FDA in the Northern District of Texas (Case No. 4:24-cv-00953-O), assigned to Judge Mark T. Pittman^[3].
• October 11, 2024. FDA voluntarily remanded its shortage-resolved decision to the agency for re-evaluation and the court paused the enforcement clock. Tirzepatide effectively returned to the shortage list during the re-review.
• December 19, 2024. FDA re-affirmed its finding that the tirzepatide shortage was resolved and published a renewed declaratory order. New enforcement-discretion windows attached — February 18, 2025 for 503A and March 19, 2025 for 503B facilities^[2].
• March 5, 2025. Judge Pittman denied the plaintiffs' motion for a preliminary injunction. The memorandum opinion held that FDA acted within its statutory authority in declaring the shortage resolved and that plaintiffs had not demonstrated a likelihood of success on the merits^[3]. OFA filed an interlocutory appeal to the Fifth Circuit.
• March 19, 2025. The 503B enforcement-discretion window expired. From this date forward FDA may take enforcement action against outsourcing facilities that continue to compound tirzepatide from bulk.
• April 30, 2026. FDA published a proposed rule to formally exclude semaglutide, tirzepatide, and liraglutide from the section 503B bulks list, on the basis that the agency identified no clinical need for outsourcing facilities to compound these substances from bulk drug substance^[4]. Public comment is open through June 29, 2026^[9].

503A vs 503B: why the distinction matters

The Federal Food, Drug, and Cosmetic Act creates two compounding regimes^[6]. Understanding which one a pharmacy operates under explains why some platforms have stopped shipping compounded tirzepatide and others claim they can continue.

• Section 503A pharmacies are traditional state-licensed compounding pharmacies. They compound for an individually-identified patient pursuant to a valid prescription. They are exempted from FDA new-drug, adequate directions for use, and current good manufacturing practice (cGMP) requirements — but only if the compounded drug is not “essentially a copy of a commercially available drug” unless the prescriber documents a clinical difference for that specific patient^[5].
• Section 503B outsourcing facilities register with FDA, comply with cGMP, and may compound in larger batches without a patient-specific prescription. They are restricted to bulk drug substances on the FDA 503B Bulks List or to drugs on the FDA shortage list^[6]. With tirzepatide off the shortage list and not on the bulks list, 503B compounding is now generally not lawful.

The April 30, 2026 proposed rule^[4] would tighten this further by formally excluding semaglutide, tirzepatide, and liraglutide from any future 503B bulks-list inclusion on a finding of no clinical need. If finalized, even a future return to shortage would not automatically re-open the 503B route.

The 503A “clinical difference” exception

This is the only remaining legal pathway for routine compounded tirzepatide in the United States. FDA's guidance under section 503A permits a pharmacy to compound a drug that is essentially a copy of a commercially available product only if “the prescriber has determined that the compounded drug product produces, for that individual patient, a clinical difference, compared with the FDA-approved commercially available drug product.”^[5] Examples FDA has historically accepted include:

• Documented allergy or sensitivity to an excipient in the FDA-approved product (preservatives, stabilizers, buffer agents). The prescriber must specify the ingredient and the reaction.
• A strength not commercially available when the prescriber documents that the patient cannot tolerate any of the FDA-approved strengths and that the requested custom strength is medically necessary — not merely preferred.
• A dosage form the patient cannot use (although for an injectable like tirzepatide this is rarely available given vial and pen options both exist on the branded side).

FDA has been explicit that cost savings, convenience, prescriber preference, and patient preference do not constitute a clinical difference^[5]. A prescriber who routinely signs off on “clinical difference” for cost-driven patients is creating documented FDA enforcement risk for themselves and the dispensing pharmacy.

What this means for current patients on compounded tirzepatide

If you are currently on compounded tirzepatide from a telehealth platform in May 2026, one of the following is happening behind the scenes:

• You have been migrated to compounded semaglutide. Several providers quietly switched their default GLP-1 formulation between February and April 2025. The patient-experience signal is a new pharmacy partner, a new vial color or labeling, and a starting-dose conversation.
• You have been migrated to branded Zepbound via cash pay. A growing share of providers act as a clinical and shipping intermediary that routes the prescription to LillyDirect or a participating retail pharmacy at $299–$449/month^[7]. Net cost to the patient is often within $50–$100 of the old compounded price.
• Your prescriber filed a 503A clinical-difference attestation. Some platforms are continuing to dispense compounded tirzepatide under a 503A documentation framework. Ask: what specific clinical difference is documented in your chart? If the answer is silence, cost, or a generic “personalized dose,” the prescription likely would not survive FDA scrutiny.
• Your prescriber is operating in the grey zone. A subset of providers are continuing to dispense compounded tirzepatide as “custom strengths” (1.25 mg, 3.75 mg, 6.25 mg) on the theory that these are not essentially a copy of any FDA-approved dose. FDA has not tested this theory in public enforcement, but it is the most common pattern seen on the warning-letter docket of competing telehealth firms.

Practical guidance: what to do now

1. Ask your provider which pathway they are using. The honest answer is one of: branded Zepbound via cash pay, compounded semaglutide (still under semaglutide 503A discretion in some states), or 503A patient-specific compounded tirzepatide with a documented clinical difference. A provider who cannot answer this question clearly is one to re-evaluate.
2. If you are on compounded tirzepatide without a documented clinical difference, the responsible course is to switch to branded Zepbound, branded Mounjaro (with a type 2 diabetes diagnosis), or branded Wegovy. The $299–$449/month LillyDirect price^[7] and the $349/month NovoCare price^[8] have closed the previous 5× cost gap.
3. If your prescriber documents a real clinical difference, save that documentation. Allergy to a specific excipient or a true intolerance to commercial strengths is a legitimate 503A indication.
4. Verify the dispensing pharmacy — PCAB accreditation, state licensure, and FDA inspection history. See our tirzepatide online pharmacy legitimacy verification guide for the checklist.
5. Watch the appeal. OFA's Fifth Circuit appeal of the March 5, 2025 preliminary-injunction denial^[3]is the principal remaining legal pathway that could re-open 503B compounding. As of May 2026 it has not done so.

Cost comparison: compounded vs branded in 2026

The 2023–2024 cash-pay gap that drove compounded tirzepatide adoption has narrowed substantially. Typical compounded-tirzepatide telehealth pricing in May 2026 ranges $179–$399/month depending on dose; LillyDirect single-dose vials are $299/month at 2.5 mg, $399/month at 5 mg, and $449/month at 7.5–15 mg^[7]. For a patient on a maintenance 10 mg or 12.5 mg dose, the net cost gap is now $50–$150/month — small enough that the regulatory certainty, FDA-approved formulation, and intact recourse rights of the branded product change the calculus for most patients. For the historical-pricing context see our compounded GLP-1 price movement over the last 12 months analysis.

Compounded semaglutide is on a parallel but slightly different track

Semaglutide was removed from the FDA shortage list in February 2025, with 503A and 503B enforcement-discretion windows that closed in April and May 2025 respectively. The analytical-framework is identical — clinical-difference documentation under 503A, with 503B effectively closed — but the FDA's historical enforcement posture on compounded semaglutide has been less aggressive than on tirzepatide. Several large telehealth platforms continued to dispense compounded semaglutide as of May 2026 under documented custom-strength or custom-formulation framings. The April 30, 2026 proposed 503B Bulks List exclusion^[4] covers semaglutide as well, signaling that this divergence is unlikely to persist. For a side-by-side regulatory comparison see our compounded vs branded GLP-1 decision guide.

Related research

• FDA warning letters to compounded GLP-1 providers — the live enforcement database, updated as letters are issued.
• Compounded tirzepatide vs Zepbound: what the bioequivalence evidence actually shows — the analytical case for and against equivalence.
• PCAB accreditation and what it means for compounding pharmacy quality — the third-party quality signal that matters.
• Cheapest compounded semaglutide providers, ranked — if a switch from tirzepatide to semaglutide is part of your pathway.

Important disclaimer. This article is educational and is not legal or medical advice. FDA enforcement posture, court rulings, and individual prescriber attestation practices change. If you are evaluating whether a specific compounded-tirzepatide prescription is lawful, consult the dispensing pharmacy's compliance officer and your prescribing clinician. URLs and dates in this article were verified live on 2026-05-28 against FDA, CourtListener, the Federal Register, and the manufacturer self-pay programs.

Last verified: 2026-05-28. Next review: every 90 days, or sooner upon a Fifth Circuit ruling in Outsourcing Facilities Association v FDA, finalization of the April 30, 2026 503B Bulks List proposed rule, or any change to LillyDirect or NovoCare cash-pay pricing.